 Nes Ziona, Israel, Nov. 11, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. Nasdaq: ENLV, the Company, a clinical-stage immunotherapy company, today announced that it will present the clinical development schedule for its Sepsis, COVID-19 and Solid Cancer programs during a fireside chat at H.C. Wainwrights 6th Annual Israel Conference. See below for more details. 